Asset Details
Do you wish to reserve the book?
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Do you wish to request the book?
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
2020
Overview
Adoptive cell therapy (ACT) is a kind of immunotherapy in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR), and ACT has made a great difference in treating multiple types of tumors. ACT is not perfect, and it can be followed by severe side effects, which hampers the application of ACT in clinical trials. One of the most promising methods to minimize side effects is to endow adoptive T cells with the ability to target neoantigens, which are specific to tumor cells. With the development of antigen screening technologies, more methods can be applied to discover neoantigens in cancer cells, such as whole-exome sequencing combined with mass spectrometry, neoantigen screening through an inventory-shared neoantigen peptide library, and neoantigen discovery via trogocytosis. In this review, we focus on the side effects of existing antigens and their solutions, illustrate the strategies of finding neoantigens in CAR-T and TCR-T therapies through methods reported by other researchers, and summarize the clinical behavior of these neoantigens.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antigens
/ Antigens, Neoplasm - chemistry
/ Antigens, Neoplasm - genetics
/ Antigens, Neoplasm - immunology
/ CAR-T
/ Cell- and Tissue-Based Therapy - adverse effects
/ Cell- and Tissue-Based Therapy - methods
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Immunotherapy, Adoptive - methods
/ Kinases
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Mice
/ Mutation
/ Peptides
/ Receptors, Chimeric Antigen - therapeutic use
/ TCR-T
